Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer.

Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer.
复制标题

DOI:
10.1002/elps.201400022
复制
发表时间:
2014-12
期刊:
影响因子:
2.9
通讯作者:
Bose, Ron
Bose, Ron
中科院分区:
生物学3区
文献类型:
--
作者:
Searleman, Adam C.;Iliuk, Anton B.;Collier, Timothy S.;Chodosh, Lewis A.;Tao, W. Andy;Bose, Ron

文献摘要

参考文献

被引文献

相似文献

Altered protein phosphorylation is a feature of many human cancers that can be targeted therapeutically. Phosphopeptide enrichment is a critical step for maximizing the depth of phosphoproteome coverage by MS, but remains challenging for tissue specimens because of their high complexity. We describe the first analysis of a tissue phosphoproteome using polymer-based metal ion affinity capture (PolyMAC), a nanopolymer that has excellent yield and specificity for phosphopeptide enrichment, on a transgenic mouse model of HER2-driven breast cancer. By combining phosphotyrosine immunoprecipitation with PolyMAC, 411 unique peptides with 139 phosphotyrosine, 45 phosphoserine, and 29 phosphothreonine sites were identified from five LC-MS/MS runs. Combining reverse phase liquid chromatography fractionation at pH 8.0 with PolyMAC identified 1571 unique peptides with 1279 phosphoserine, 213 phosphothreonine, and 21 phosphotyrosine sites from eight LC-MS/MS runs. Linear motif analysis indicated that many of the phosphosites correspond to well-known phosphorylation motifs. Analysis of the tyrosine phosphoproteome with the Drug Gene Interaction database uncovered a network of potential therapeutic targets centered on Src family kinases with inhibitors that are either FDA-approved or in clinical development. These results demonstrate that PolyMAC is well suited for phosphoproteomic analysis of tissue specimens.
DOI: 10.1056/nejmoa040938
发表时间: 2004-05-20
影响因子: 158.5
作者:
Lynch, TJ;Bell, DW;Haber, DA
通讯作者: Haber, DA
DOI: 10.3892/ijo.2013.2195
发表时间: 2014-02
影响因子: 5.2
作者:
Chung SS;Giehl N;Wu Y;Vadgama JV
通讯作者: Vadgama JV
DOI: 10.1056/nejmoa062867
发表时间: 2006-12-07
影响因子: 158.5
作者:
Druker, Brian J.;Guilhot, Francois;Larson, Richard A.
通讯作者: Larson, Richard A.
DOI: 10.1038/nbt1146
发表时间: 2005-11-01
影响因子: 46.9
作者:
Schwartz, D;Gygi, SP
通讯作者: Gygi, SP
DOI: 10.1158/2159-8290.cd-12-0349
发表时间: 2013-02
期刊: Cancer discovery
影响因子: 28.2
作者:
Bose R;Kavuri SM;Searleman AC;Shen W;Shen D;Koboldt DC;Monsey J;Goel N;Aronson AB;Li S;Ma CX;Ding L;Mardis ER;Ellis MJ
通讯作者: Ellis MJ